A young Canadian, Gurmoh Singh Gill, is facing a rare disease called hereditary spastic paraplegia (HSP), becoming the only child in the country with this specific genetic mutation. His parents, both dentists from Surrey, B.C., have embarked on a nationwide journey to raise awareness and funds for research. Despite the challenges, a new genetic therapy being developed at the Montreal Neurological Institute is offering hope for Gurmoh and potentially many others with neurological and genetic rare diseases.
Gurmoh’s parents have already raised over $2.6 million through crowdfunding and fundraisers, but estimate that $6 to $8 million will ultimately be needed for his treatment. The groundbreaking therapy aims to correct the genetic mutation responsible for his condition, potentially restoring his abilities as the disease progresses.
Dr. Ziv Gan-Or, leading the research at the Neuro, emphasizes the innovative approach of this therapy, focusing on gene editing technology that could pave the way for effective treatments for a wide range of rare neurological disorders. The family’s journey across Canada not only seeks support for Gurmoh but also highlights the broader impact this research could have on the 3.2 million Canadians affected by such diseases.
As they head to their final stop in Ottawa, the Gills carry with them the hope and encouragement of thousands of supporters, urging for swift action and support from government authorities. Their tireless advocacy underscores the urgent need for attention and funding to address rare diseases affecting many Canadians like Gurmoh.
